This review presents modern strategies for the prevention and treatment of cardiotoxicity induced by the most commonly used anticancer drugs such as anthracycline antibiotics, monoclonal antibodies, tyrosine kinase inhibitors. There are a large number of conflicting data on ways to overcome the cardiotoxicity of anticancer drugs. The creation of a complex of diagnostic measures will allow to identify the earliest signs of heart damage during chemotherapy and to develop timely preventive measures to prevent cardiotoxicity, improve the quality of life and prognosis of patients. Currently, a large number of small publications on the prevalence, prediction and prevention of cardiotoxicity in cancer patients, including the primary and secondary prevention of cardiotoxicity, are available. Beta-blockers and inhibitors of angiotensin-converting enzyme most often use as cardioprotective agents. There is evidence of poor tolerability of treatment with these drugs for young patients. Most drugs reduce blood pressure, which can adversely affect the health of patients without associated hypertension. Coordinated work between cardiologists and oncologists is needed to create common terminology, to define cardiovascular events and create registers, meta-analyzes, generally accepted recommendations, guidelines for the management of patients at risk of developing cardiotoxicity. This review used published articles the Scopus, Pubmed database, articles from The New England Journal of Medicine, Annals of Oncology, and periodicals of the Russian Federation over the past 10 years, as well as publications from previous years.

Full Text

Restricted Access

About the authors

A. A Ibragimova

N.I. Pirogov Russian National Research Medical University

117997, Moscow, Russian Federation

E. I Emelina

N.I. Pirogov Russian National Research Medical University

117997, Moscow, Russian Federation

Gennady E. Gendlin

N.I. Pirogov Russian National Research Medical University

Email: rgmugt2@mail.ru
117997, Moscow, Russian Federation
doktor of medical sciences, professor, Department of Hospital Therapy №. 2 “N. I. Pirogov Russian National Research Medical University”; 117997, Moscow, Russian Federation

I. G Nikitin

N.I. Pirogov Russian National Research Medical University

117997, Moscow, Russian Federation


  1. Mariotto A.B., Yabroff K.R., Shao Y., Feuer E.J., Brown M.L. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103: 117-28. doi: 10.1093/jnci/djq495
  2. Koelwyn G.J., Jones LW, Moslehi J. Unravelling the causes of reduced peak oxygen consumption in patients with cancer: complex, timely, and necessary. J Am Coll Cardiol. 2014; 64: 1320-2. doi: 10.1016/j. jacc.2014.07.949
  3. Markman T.M., Markman M. Cardio-Oncology: mechanisms of cardiovascular toxicity. Published online 2018 Jan 25. doi: 10.12688/f1000research.12598.1
  4. Wenners Ballard, Justin Vader Prevention of Cardiotoxicity in the Cancer Patient. Curr Cardiovasc Risk Rep (2017) 11: 31 doi: 10.1007/s12170-017-0558-1
  5. Curigliano G., Cardinale D., Suter T., et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: Esmo clinical practice guidelines. AnnOncol. 2012; 23(suppl 7): 155-66. doi: 10.1093/annonc/mds293
  6. Carrie G. Lenneman, Douglas B. Sawyer Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment. Circ Res. 2016; 118(6): 1008-20. doi: 10.1161/CIRCRESAHA.115.303633
  7. Harris L., Batist G., Belt R., Rovira D.,.Navari R. et al. TLC D-99 Study Group. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002; 94: 25-36.
  8. Vejpongsa P., Yeh E.T. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am CollCardiol. 2014; 64(9): 938-45. doi: 10.1016/j.jacc.2014.06.1167.
  9. Shaikh F., Dupuis L.L., Alexander S. et al. Cardioprotection and second malignant neoplasms associated with dexrazoxane in children receiving anthracycline chemotherapy: a systematic review and meta-analysis. J Natl Cancer I 2016; 108. doi: 10.1093/inci/djv357
  10. Armenian S.H., Lacchetti C. et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2017; 35: 893- 911. doi: 10.1200/JCO.2016.70.5400.
  11. Daniel Bernstein, Giovanni Fajardo, Mingming Zhao. The role of β-adrenergic receptors in heart failure: Differential regulation of cardiotoxicity and cardioprotection. ProgPediatrCardiol. 2011; 31(1): 35-8. doi: 10.1016/j.ppedcard.2010.11.007
  12. Kenichi Watanabe, Wawaimuli Arozal et al. The Role of Carvedilol in the Treatment of Dilated and Anthracyclines-Induced Cardiomyopathy. Pharmaceuticals (Basel). 2011; 4(5): 770-81. doi: 10.3390/ph4050770
  13. Bosch X., Rovira M., Sitges M., Domиnech A. et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial. J Am CollCardiol. 2013; 61: 2355-62. doi: 10.1016/j.jacc.2013.02.072.
  14. Yun S., Vincelette N.D., Abraham I. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. PostgradMed J. 2015; 91: 627-33. doi: 10.1136/postgradmedj-2015-133535.
  15. Gulati G Heck SL Ree AH Hoffmann P et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016; 37: 1671-80.
  16. Pravdivtseva E.V., Poteshkina N. G., Svanadze A.M., Rilskiy D. S. Prevention of antracyclin antibiotic doxorubicin сardiotoxicity: a role of ace-inhibitor perindopril. Clinicist. 2011; 5(3): 55-60. https://doi.org/10.17650/1818-8338-2011-3-55-60
  17. Seicean S., Seicean A., Plana J.C., Budd G.T., Marwick T.H. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am CollCardiol. 2012; 60: 2384-90. doi: 10.1016/j.jacc.2012.07.067
  18. Vasyuk1 Yu. A., Shkolnik1 E.L., Nesvetov1 V.V., Shkolnik L.D., Varlan G.V., A.V.Pilshchikov A.V. Anthracycline cardiotoxicity: Prospects for using ivabradine Cardiosomatica. 2012; 4: 65-9. https://con-med.ru/magazines/cardiosomatika/cardiosomatika-04-2012/antratsiklinovaya_kardiotoksichnost_perspektivy_ispolzovaniya_ivabradina
  19. Schirmer S.H., Degen A., BaumhКkel M. et al. Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. Eur Heart J. 2012; 33 (10): 1223-31. doi: 10.1093/eurheartj/ehr255
  20. Jing Zhang, Xiaohai Cui, Yan Yan, Min Li, Ya Yang, Jiansheng Wang, Jia Zhang. Research progress of cardioprotective agents for prevention of anthracyclinecardiotoxicity. Am J Transl Res. 2016; 8(7): 2862-75. www.ajtr.org /ISSN:1943-8141/AJTR0024108
  21. Cardinale D., Ciceri F., Latini R. et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial (2018). European Journal of Cancer, 94. doi: 10.1016/j.ejca.2018.02.005
  22. Golubtsov O.Y., Tyrenko V.V., Lyutov V.V., Maslyakov V.V., Makiev R.G. Сardiovascular complications of anticancer therapy. 2017; 2. https://elibrary.ru/item.asp?id=29036195
  23. Pituskin E., Mackey J.R., Koshman S. et al. Multidisciplinary approach to novel therapies in cardio-oncology https://www.science-education.ru/ru/article/view?id=26380research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J ClinOncol. 2017; 35(8): 870-7. https://doi.org/10.1200/JCO.2016.68.7830.
  24. Oliveira G.H., Qattan M.Y., Al-Kindi S., Park S.J. Advanced heart failure therapies for patients with chemotherapy-induced cardiomyopathy. CircHeartFail. 2014; 7: 1050-8. doi: 10.1161/ CIRCHEARTFAILURE.114.001292.
  25. Oliveira GH, Hardaway BW, Kucheryavaya AY, Stehlik J, Edwards LB, Taylor DO. Characteristics and survival of patients with chemotherapyinduced cardiomyopathy undergoing heart transplantation. J Heart Lung Transplant. 2012; 31: 805-10. doi: 10.1016/j.healun.2012.03.018.
  26. Huang C, Zhang X, Ramil JM, Rikka S, Kim L, Lee Y, GudeNA,Thistlethwaite PA, Sussman MA, Gottlieb RA, Gustafsson AB. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation. 2010; 121: 675-83. doi: 10.1161/ CIRCULATIONAHA.109.902221.
  27. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J ClinOncol. 2007; 25: 3525-33. doi: 10.1200/JCO.2007.11.0106.
  28. Onitilo AA, Engel JM, Stankowski RV. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. TherAdv Drug Saf. 2014; 5: 154-66. doi: 10.1177/2042098614529603.
  29. Bovelli D, Plataniotis G, Roila F; ESMO Guidelines Working Group.Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010; 21(suppl5): 277-82. doi: 10.1093/annonc/mdq200.



Abstract - 30

PDF (Russian) - 0


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies